Treace to Report First Quarter 2026 Financial Results on May 8, 2026

Treace Medical Concepts (NasdaqGS: TMCI) will report first quarter 2026 financial results before market open on May 8, 2026.

Rhea-AI Summary

Treace Medical Concepts (NasdaqGS: TMCI) will report first quarter 2026 financial results before market open on May 8, 2026. Management will host a conference call at 8:00 AM ET the same day. A live and archived webcast will be available on the company investor relations website.

Investors must register to receive dial-in numbers and a unique PIN to join and ask questions.

Argus Apr 24 session

+8.79% close to close Open Argus

Details

News Market Reaction – TMCI

In the Apr 24 session, TMCI gained 8.79%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +8.8% in the session following this news. A strong positive reaction aligns with inv...

Analysis

The stock moved +8.8% in the session following this news. A strong positive reaction aligns with investor focus on upcoming catalysts. TMCI’s history shows negative moves after prior updates, including product news and earnings, despite constructive fundamentals. A sharp upside move of at least 5% around this earnings-date notice could reflect expectations for the May 8 call to clarify growth, margins, or guidance. With shares far below the $7.78 52‑week high, traders would still be weighing how sustainable any rebound might be.

Key Figures

Earnings release date: May 8, 2026 Conference call time: 8:00 am ET Current share price: $1.82 +5 more

Earnings release date

May 8, 2026

Planned Q1 2026 financial results release before market open

Conference call time

8:00 am ET

Start time for Q1 2026 results call

Current share price

$1.82

Price before Q1 2026 earnings-date announcement; down 2.67% on the day

52-week high

$7.78

Upper end of TMCI’s 52-week trading range pre-announcement

52-week low

$1.17

Lower end of TMCI’s 52-week trading range pre-announcement

20-day avg volume

1,019,262 shares

Benchmark versus today’s 432,053 shares traded

Market capitalization

$118,555,518

Equity value prior to Q1 2026 earnings-date news

200-day moving average

$4.07

Longer-term trend indicator; shares trade below this level

Historical Context

5 past events · Latest: Apr 07

5 events

1. Apr 07

   Product launch update

   24h Move

   -6.9%

   Announced first surgical cases using new SuperBite Compression Screw System.

2. Feb 27

   Earnings results

   24h Move

   -11.4%

   Reported Q4 and full-year 2025 results and issued 2026 financial guidance.

3. Feb 24

   Clinical data update

   24h Move

   -2.0%

   Highlighted positive interim clinical data and new product innovations at ACFAS.

4. Feb 12

   Earnings date change

   24h Move

   -2.1%

   Updated the scheduled date for Q4 and full-year 2025 earnings release.

5. Jan 13

   Preliminary revenue

   24h Move

   -3.2%

   Issued preliminary, unaudited Q4 and full-year 2025 revenue ranges.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PONTE VEDRA, Fla., April 24, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the first quarter 2026 before the start of trading on Friday, May 8, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET.

Investors interested in listening to the conference call may do so by registering. Once registered, participants will receive dial-in numbers and a unique pin to join the call and ask questions. A live and archived webcast of the event will be available on the Company’s investor relations website at https://investors.treace.com/.

Internet Posting of Information
Treace routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.treace.com. The Company encourages investors and potential investors to consult the Treace website regularly for important information about Treace.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion and related midfoot deformities. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 67 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty^®3D Bunion Correction^® System – a combination of instruments, implants, and surgical methods designed to surgically correct all three planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. To further support the needs of surgeons and bunion patients, Treace offers its Adductoplasty^® Midfoot Correction System, designed for reproducible surgical correction of midfoot deformities, two systems for minimally invasive osteotomy procedures, namely the Nanoplasty^® 3D Minimally Invasive Bunion Correction System and the Percuplasty™ Percutaneous 3D Bunion Correction System, and the SpeedMTP^® MTP Fusion System. Treace continues to expand its footprint in the marketplace by extending its SpeedPlate^® rapid compression implant platform to new applications, as well as providing surgeons with advanced digital solutions with its IntelliGuide™ patient specific, pre-op planning and cut guide technology. For more information, please visit www.treace.com.

To learn more about Treace, connect with us on LinkedIn, X, Facebook and Instagram.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Philip Trip Taylor
IR@treace.net

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Treace (TMCI) release Q1 2026 financial results?

Treace will release Q1 2026 results before trading on May 8, 2026. According to Treace, the release precedes a management conference call at 8:00 AM ET the same day and a live webcast will be posted on the company investor relations website.

What time and how can I join Treace's (TMCI) May 8, 2026 conference call?

The conference call begins at 8:00 AM ET on May 8, 2026. According to Treace, investors must register in advance to receive dial-in numbers and a unique PIN to join the call and ask questions.

Where will Treace (TMCI) post the live webcast and archive of the May 8 call?

Treace will host a live and archived webcast on its investor relations website at https://investors.treace.com/. According to Treace, the webcast will be available for listening during the call and afterward via the archived replay.

Do I need to register to participate in Treace's (TMCI) investor call on May 8, 2026?

Yes. According to Treace, investors must register to receive dial-in numbers and a unique PIN. Registration provides access to the live call, question submission, and instructions for the webcast.

Where does Treace recommend investors look for ongoing company updates and materials?

Treace recommends checking the Investor Relations section of its website for important updates. According to Treace, the company routinely posts investor‑relevant information at www.treace.com and encourages regular consultation of that section.